Healthcare >> CEO Interviews >> December 30, 1999
JESSE I. TREU has been a General Partner of Domain Associates
since 1985. He has been a Director of over 20 early-stage
healthcare companies, 13 of which subsequently went public. These
include Biosite Diagnostics, GelTex Pharmaceuticals Genzyme),
Inspire Pharmaceuticals, NPS Pharmaceuticals, Sepracor,
OraPharma, and Trimeris. Prior to the formation of Domain, Mr.
Treu was VP of the predecessor organization to The Wilkerson
Group and its venture capital arm, CW Ventures. While at CW
Ventures, he served as President and CEO of Microsonics, a
pioneer in computer image processing for cardiology. From 1977
through 1982, Mr. Treu led new product development and marketing
planning for immunoassay and histopathology products at Technicon
Corporation (now Bayer Diagnostics). Mr. Treu began his career
with GE in 1973, initially as a research scientist developing
thin film optical sensors for immunoassay testing, and
subsequently serving on the corporate staff with responsibility
for technology assessment and strategic planning. Profile
structured?
Mr. Treu: Domain Associates is a venture capital firm that has
been in operation since 1985. Our specialization is
